gdc

June 2019 Vol 5 No 3

Cancer and Me
LymphomaPatient Stories
Brigid Wallace contemplates the choices she made when living in the “new normal” after her cancer diagnosis. She describes the struggles and personal victories that tested her faith and strength after she learned she had non-Hodgkin lymphoma.
Communicating About Cancer—More Fun Than Jury Duty
Family MembersFrom Your Navigator
“A cancer diagnosis can derail even the best methods of communication,” says oncology social worker Katie Narvarte. She offers tips on how to address difficult topics related to cancer, and how to avoid saying the wrong things.
What to Eat to Combat Cancer-Related Fatigue
Nutrition & CancerSide-Effects Management
Fatigue is a common complaint of people facing cancer that can affect them during and after treatment. Registered Dietitian Julie Lanford provides tips on energy-boosting foods and simple nourishment ideas to help combat fatigue during cancer.
You Are Perfectly Healthy, It’s Just the “Good Cancer”
Patient AdvocacyPatient StoriesProstate Cancer
Dennis Golden was an active, fit, 70-year-old when he learned he had prostate cancer. He was surprised to discover that few men know the warning signs and how potentially serious it can be. In response, he formed the National Prostate Cancer Awareness Foundation to educate men about this disease.
Tibsovo Approved for First-Line Treatment of Patients with Acute Myeloid Leukemia and IDH1 Mutation
FDA Approvals, News & UpdatesLeukemia
In May 2019, the FDA approved Tibsovo for the treatment of older patients with newly diagnosed acute myeloid leukemia (AML) and an IDH1 mutation, or for patients with AML who are unable to use intensive chemotherapy.
Piqray New Treatment Approved for Metastatic Breast Cancer and PI3KCA Mutation
Breast CancerFDA Approvals, News & Updates
In May 2019, the FDA approved Piqray (alpelisib), the first PI3K inhibitor for the treatment of metastatic breast cancer with a PI3KCA mutation in postmenopausal women, and in men. An FDA spokesperson said it was the first treatment “to demonstrate a clinically meaningful benefit” for this type of breast cancer.
Balversa First Targeted Drug Approved for Metastatic Bladder Cancer with FGFR Genetic Alterations
Bladder CancerFDA Approvals, News & Updates
In April 2019, the FDA approved Balversa, an FGFR kinase inhibitor, for the treatment of adults with advanced or metastatic bladder cancer and an FGFR genetic alteration, as determined by an FDA-approved diagnostic test. This is the first FDA-approved targeted drug for patients with this specific genetic mutation.
FDA Calls Attention to Risk Associated with Breast Implants: Anaplastic Large-Cell Lymphoma
Breast CancerLymphomaSurvivorship
In February 2019, the FDA issued a letter to raise awareness of the risk for a rare type of lymphoma, BIA-ALCL, that is linked to all types of breast implants. Although this is an uncommon reaction to implants, all women who have or intend to get an implant after breast cancer should be aware of this risk. Learn more about this risk here.
Page 1 of 3
Results 1 - 10 of 22

Subscribe to CONQUER: the patient voice magazine

Receive timely cancer news & updates, patient stories, and more.

Country